Paramita Therapeutics, Inc. (Paramita) began operations in 2018 and is an early-stage biotech startup focused on development of water-soluble multivalent technologies and targeted cancer therapeutics. After the pre-seed fund obtained in late 2018, we have developed our new water-soluble multivalent platform and generated proof-of-concept data in mice. Paramita is now seed-funded by National Science Foundation (NSF) through a Phase 1 SBIR Award to develop multivalent peptide conjugates for a dual-function therapeutic and vaccine product of COVID-19. We are actively seeking for funds to continue with our research and development of our cancer drugs and dual-function therapeutic/vaccine product. Our Founders include Drs. Sang Van, Jack Bui, and Sue Zhong.